These observations may also have therapeutic implications, as pharmacological inhibition of the RAAS or mineralocorticoid receptor blockade has been shown to attenuate cardiac and renal fibrosis in experimental and clinical settings.50,51 Such interventions might therefore represent potential strategies to mitigate the maladaptive cardio–renal signalling observed after MI. The gene discussed is NR3C2; the disease is renal fibrosis.